首页> European urology> Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer.

Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer.

导出 LinkOut

翻译打印收藏纠错

第一作者： Adam,Sharp

第一单位： The Institute for Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, London, UK.

作者： Adam,Sharp ^[1] ; Jon C,Welti ^[2] ; Maryou B K,Lambros ^[2] ; David,Dolling ^[2] ; Daniel Nava,Rodrigues ^[2] ; Lorna,Pope ^[2] ; Caterina,Aversa ^[3] ; Ines,Figueiredo ^[2] ; Jennifer,Fraser ^[2] ; Zai,Ahmad ^[2] ; Changxue,Lu ^[4] ; Pasquale,Rescigno ^[5] ; Michael,Kolinsky ^[6] ; Claudia,Bertan ^[2] ; George,Seed ^[2] ; Ruth,Riisnaes ^[2] ; Susana,Miranda ^[2] ; Mateus,Crespo ^[2] ; Rita,Pereira ^[2] ; Ana,Ferreira ^[2] ; Gemma,Fowler ^[2] ; Berni,Ebbs ^[2] ; Penny,Flohr ^[2] ; Antje,Neeb ^[2] ; Diletta,Bianchini ^[3] ; Antonella,Petremolo ^[3] ; Semini,Sumanasuriya ^[1] ; Alec,Paschalis ^[1] ; Joaquin,Mateo ^[7] ; Nina,Tunariu ^[3] ; Wei,Yuan ^[2] ; Suzanne,Carreira ^[2] ; Stephen R,Plymate ^[8] ; Jun,Luo ^[4] ; Johann S,de Bono ^[9]

作者单位： The Institute for Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, London, UK. ^[1] The Institute for Cancer Research, London, UK. ^[2] The Royal Marsden NHS Foundation Trust, London, UK. ^[3] Johns Hopkins University School of Medicine, Baltimore, MD, USA. ^[4] The Institute for Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, London, UK; University of Naples Federico II, Naples, Italy. ^[5] University of Alberta, Edmonton, Alberta, Canada. ^[6] Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. ^[7] University of Washington and VAPSHCS GRECC, Seattle, WA, USA. ^[8] The Institute for Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, London, UK. Electronic address: Johann.de-Bono@icr.ac.uk. ^[9]

关键词 Androgen receptor Androgen receptor splice variant-7 Biomarker Liquid biopsy Metastatic castration-resistant prostate cancer Prognostic